Laughing Water Capital’s recent decision to add AnaptysBio (ANAB) has drawn attention because it hinges on two factors: royalty income from the cancer drug Jemperli and an imminent commercial trial with partner GSK.

Despite the recent legal spotlight, AnaptysBio’s share price has been volatile, with a 1-day share price return down 10.46% and a 7-day share price return down 7.15%. However, a year-to-date share price return of 39.07% sits alongside a very large 1-year total shareholder return of 252.16% and a 3-year total shareholder return of almost 4x. This suggests long term holders have already seen substantial gains even as near term momentum has cooled.

If you are weighing AnaptysBio against other opportunities in healthcare, it may be worth checking a curated list of 40 healthcare AI stocks as a starting point for further ideas.

The stock has already delivered a very large 1 year gain, yet recent weakness and a sizeable gap to analyst price targets pull in the opposite direction. Is AnaptysBio better approached as a buy now or as a wait and watch?

Most Popular Narrative: 30.5% Undervalued

At a last close of $62.51 versus a narrative fair value of $90, the current pricing of AnaptysBio sits well below what the featured thesis implies.

Either ANAB wins or settles in the next few months and the stock re-rates toward the high end of the range, or ANAB loses, and you own a 95%-margin royalty stream worth $80.

You can also sell an OTM covered call if you want to size this a bit bigger.

Curious what kind of revenue growth, profitability shift, and royalty stream durability sit behind that $90 fair value for AnaptysBio? The full narrative spells out the royalty timelines, projected earnings ramp, and how that feeds into the valuation gap, but keeps some crucial assumptions under the hood until you read it in context.

Result: Fair Value of $90 (UNDERVALUED)

However, AnaptysBio’s thesis still relies on ongoing royalty strength and a favorable legal outcome, so weaker drug performance or an adverse court decision could challenge this narrative.

Next Steps

If the split view on AnaptysBio so far has you unsure, take a closer look at the underlying data now and shape your own stance using the 2 key rewards and 1 important warning sign.

Looking for more ideas beyond AnaptysBio?

Do not stop with AnaptysBio alone; broaden your watchlist using focused stock ideas so you are not relying on a single company or theme.

• Target dependable cash generators by checking stocks in the 8 dividend fortresses for potential income ideas that might suit a diversified portfolio.
• Hunt for quality at a discount as you scan the 44 high quality undervalued stocks to spot companies where fundamentals and pricing currently appear out of sync.
• Spot potential future leaders early by reviewing the screener containing 20 high quality undiscovered gems before they gain wider attention and become crowded trades.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.